X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs GLENMARK PHARMA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH GLENMARK PHARMA STERLING BIOTECH/
GLENMARK PHARMA
 
P/E (TTM) x -1.8 13.9 - View Chart
P/BV x 0.1 3.9 1.8% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 STERLING BIOTECH   GLENMARK PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
GLENMARK PHARMA
Mar-16
STERLING BIOTECH/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs111,262 0.8%   
Low Rs3672 0.5%   
Sales per share (Unadj.) Rs26.8270.6 9.9%  
Earnings per share (Unadj.) Rs-15.024.9 -60.1%  
Cash flow per share (Unadj.) Rs-5.534.4 -15.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs54.9151.3 36.3%  
Shares outstanding (eoy) m267.87282.16 94.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.6 7.3%   
Avg P/E ratio x-0.538.9 -1.2%  
P/CF ratio (eoy) x-1.328.1 -4.5%  
Price / Book Value ratio x0.16.4 2.0%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m1,862272,778 0.7%   
No. of employees `0001.410.0 13.5%   
Total wages/salary Rs m54713,782 4.0%   
Avg. sales/employee Rs Th5,303.37,614.9 69.6%   
Avg. wages/employee Rs Th403.81,374.8 29.4%   
Avg. net profit/employee Rs Th-2,959.0700.2 -422.6%   
INCOME DATA
Net Sales Rs m7,18176,340 9.4%  
Other income Rs m43356 12.0%   
Total revenues Rs m7,22376,696 9.4%   
Gross profit Rs m94714,172 6.7%  
Depreciation Rs m2,5432,691 94.5%   
Interest Rs m4,3771,789 244.7%   
Profit before tax Rs m-5,93110,048 -59.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9243,028 -63.5%   
Profit after tax Rs m-4,0077,019 -57.1%  
Gross profit margin %13.218.6 71.0%  
Effective tax rate %32.430.1 107.6%   
Net profit margin %-55.89.2 -606.8%  
BALANCE SHEET DATA
Current assets Rs m14,33559,096 24.3%   
Current liabilities Rs m49,80940,018 124.5%   
Net working cap to sales %-494.025.0 -1,976.7%  
Current ratio x0.31.5 19.5%  
Inventory Days Days40375 538.1%  
Debtors Days Days171119 143.2%  
Net fixed assets Rs m55,43239,075 141.9%   
Share capital Rs m268282 94.9%   
"Free" reserves Rs m13,93530,281 46.0%   
Net worth Rs m14,70142,703 34.4%   
Long term debt Rs m9,47824,873 38.1%   
Total assets Rs m73,988111,026 66.6%  
Interest coverage x-0.46.6 -5.4%   
Debt to equity ratio x0.60.6 110.7%  
Sales to assets ratio x0.10.7 14.1%   
Return on assets %0.57.9 6.3%  
Return on equity %-27.316.4 -165.8%  
Return on capital %-6.417.5 -36.7%  
Exports to sales %25.943.3 59.8%   
Imports to sales %0.27.4 2.3%   
Exports (fob) Rs m1,86033,044 5.6%   
Imports (cif) Rs m125,672 0.2%   
Fx inflow Rs m1,86036,945 5.0%   
Fx outflow Rs m2561,066 0.0%   
Net fx Rs m1,835-24,122 -7.6%   
CASH FLOW
From Operations Rs m1,7193,449 49.8%  
From Investments Rs m-3,148-8,802 35.8%  
From Financial Activity Rs m1,4266,986 20.4%  
Net Cashflow Rs m-3934 -0.4%  

Share Holding

Indian Promoters % 33.9 48.3 70.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 6.9 -  
FIIs % 9.9 34.4 28.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 10.5 374.3%  
Shareholders   21,482 56,727 37.9%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Aug 18, 2017 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS